| Name | NVP-2 |
| Description | NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases (IC50: 0.584 μM, 0.706 μM, and 0.605 μM, respectively). |
| In vitro | NVP-2 exhibits anti-proliferative activity against leukemia cells, specifically targeting KOPT-K1, Jurkat, P12-ICHIKAWA, DU.528, MOLT 16, HSB-2, PF-382, SKW-3, SUP-T11, DND-41, and HPB-ALL cells with IC50 values of 0.1688 μM, 0.1233 μM, 0.5736 μM, 0.1575 μM, 0.1620 μM, 0.1585 μM, 0.1808 μM, 0.2589 μM, 0.0918 μM, and 0.3023 μM, respectively. NVP-2 (0-10 nM; 72 hours) demonstrates CRBN-dependent anti-proliferative and pro-apoptotic effects in MOLT4 cells (IC50: 9 nM). At 250 nM for 24 hours, NVP-2 induces apoptosis in MOLT4 cells, increasing caspase-3 and γH2A.X expression, although this effect is significantly reduced upon compound washout. Additionally, NVP-2 (250 nM-1 μM; 6 hours) engages CDK9 in both wildtype and CRBN - / - MOLT4 cells without affecting CDK2 and CDK7. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.8 mM), Sonication is recommended. DMSO : 250 mg/mL (487.26 mM), Sonication is recommended.
|
| Keywords | NVP-2 | NVP2 | NVP 2 | Leukemia | Inhibitor | inhibit | Cyclin dependent kinase | CRBN | CDK9 | CDK | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Covalent Inhibitor Library | Anti-Cancer Compound Library |